Isabelle Mahé/LinkedIn
Aug 1, 2025, 13:11
Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
Isabelle Mahé, University Professor, Hospital Practitioner in Internal Medicine, shared an insightful post on LinkedIn:
”APICAT Study : reduced dose of apixaban for extended treatment in patient with Cancer associated Thrombosis.
A practice changing study.”
Read the full article here.
Article: ”Apixaban for Cancer-Associated Venous Thromboembolism”
Authors: Zhuo Shao, Xinyu Zhai
Stay updated on the latest scientific advancements in the field of thrombosis with Hemostasis Today.
-
Mar 19, 2026, 18:29Rameez Ashraff: Have You Noticed Neutrophil Inclusions in a Thrombocytopenia Smear?
-
Mar 19, 2026, 18:07Leonardo Roever: A Consensus Framework for Biomarker Research and Clinical Translation in Stroke
-
Mar 19, 2026, 17:49Matteo Foschi: Breaktrough Stroke on Oral Anticoaugulants for Atrial Fibrillation
-
Mar 19, 2026, 17:30UK Haemophilia Society Continues to Empower Individuals and Families Through Advocacy, Education, and Community Support – WFH
-
Mar 19, 2026, 17:20Dimitrios Nikas: Stroke During TAVI Procedures Still Remains Noticeable High
-
Mar 19, 2026, 17:14Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
-
Mar 19, 2026, 17:03How Personal Experiences Can Support Self‑Advocacy and Help Improve Healthcare Outcomes – Hemophilia Alliance
-
Mar 19, 2026, 16:54X. Long Zheng: Unpacking the Real-World Challenges of ADAMTS13 on ISTH Pulse Podcast
-
Mar 19, 2026, 16:50Zain Khalpey: Predictive Imaging and AI in Aortic Dissection Risk Assessment